Melanocyte-Stimulating Hormone (Alpha-MSH)

Overview

Alpha-melanocyte-stimulating hormone (alpha-MSH) is a 13-amino-acid neuropeptide produced by post-translational processing of proopiomelanocortin (POMC) in the pituitary gland, hypothalamus, skin, and various peripheral tissues. It is the most potent and well-characterized endogenous agonist of the melanocortin 1 receptor (MC1R) and plays central roles in three major physiological systems: pigmentation, energy homeostasis/appetite regulation, and anti-inflammatory signaling.

Alpha-MSH corresponds to residues 1-13 of ACTH (corticotropin) but differs from the parent hormone through two critical post-translational modifications: N-terminal acetylation of the serine residue and C-terminal amidation of the valine residue. These modifications dramatically increase alpha-MSH's potency at MC1R and MC3R/MC4R while rendering it resistant to aminopeptidase degradation, extending its biological half-life relative to unmodified peptide fragments.

The melanocortin system, of which alpha-MSH is the central ligand, has emerged as one of the most physiologically important peptide signaling networks. Melanocortin receptors (MC1R through MC5R) regulate processes ranging from skin and hair pigmentation to body weight, sexual behavior, adrenal function, and immune modulation. Dysregulation of melanocortin signaling is implicated in obesity (MC4R loss-of-function mutations), inflammatory diseases, and pigmentation disorders.

Alpha-MSH also holds significance in peptide research as the parent molecule from which KPV — the C-terminal anti-inflammatory tripeptide (residues 11-13) — is derived, and as the endogenous ligand that synthetic melanocortin analogs such as Melanotan I, Melanotan II, and bremelanotide (PT-141) were designed to mimic.

Structure

Alpha-MSH is a tridecapeptide with N-terminal acetylation and C-terminal amidation:

Sequence: Ac-Ser-Tyr-Ser-Met-Glu-His-Phe-Arg-Trp-Gly-Lys-Pro-Val-NH₂

• Molecular formula: C₇₇H₁₀₉N₂₁O₁₉S₁
• Molecular weight: 1,664.88 Da
• CAS Number: 581-05-5
• Precursor: POMC -> ACTH(1-39) -> alpha-MSH(1-13)
• Post-translational modifications: N-alpha-acetylation (Ser1), C-terminal amidation (Val13)

Key structural motifs:

• His-Phe-Arg-Trp (residues 6-9) — the core melanocortin pharmacophore shared across all MSH peptides and essential for MC receptor binding
• Residues 11-13 (Lys-Pro-Val) — the KPV tripeptide fragment retaining anti-inflammatory activity independent of melanocortin receptor signaling
• N-acetylation — increases MC1R binding affinity approximately 10-100 fold relative to des-acetyl-alpha-MSH
• C-amidation — enhances metabolic stability and receptor potency

The His-Phe-Arg-Trp tetrapeptide pharmacophore has served as the template for virtually all synthetic melanocortin receptor ligands, including cyclic peptide agonists (Melanotan II, bremelanotide) and small-molecule melanocortin drugs.

Mechanism of Action

Melanocortin Receptor Activation

Alpha-MSH activates multiple melanocortin receptors with varying potency and tissue-specific consequences:

MC1R — Pigmentation: MC1R is expressed on melanocytes in the skin and hair follicles. Alpha-MSH binding activates adenylyl cyclase via Gs coupling, increasing cAMP levels and activating the MITF (microphthalmia-associated transcription factor) pathway. MITF drives transcription of tyrosinase, TRP-1, and TRP-2 — the enzymes catalyzing melanin biosynthesis. The net effect is a switch from pheomelanin (red/yellow pigment) to eumelanin (brown/black pigment) production, producing skin darkening and photoprotection.

MC3R/MC4R — Energy Homeostasis: In the hypothalamic arcuate nucleus, POMC neurons release alpha-MSH onto MC3R and MC4R-expressing neurons in the paraventricular nucleus and lateral hypothalamus. MC4R activation is anorexigenic — it suppresses appetite and increases energy expenditure. This pathway is tonically opposed by agouti-related peptide (AgRP), an endogenous MC3R/MC4R inverse agonist released by neighboring NPY/AgRP neurons. The POMC/alpha-MSH vs. AgRP balance is the central integrator of energy homeostasis signals from leptin, insulin, and ghrelin.

Loss-of-function mutations in MC4R are the most common monogenic cause of severe early-onset obesity in humans, underscoring the critical importance of alpha-MSH-MC4R signaling in body weight regulation.

MC5R — Exocrine Function: MC5R, expressed in sebaceous glands and various exocrine tissues, modulates sebum production and exocrine secretion. MC5R knockout mice exhibit severe defects in water repulsion of fur due to altered sebaceous lipid composition.

Anti-Inflammatory Signaling

Alpha-MSH exerts potent anti-inflammatory effects through multiple mechanisms:

• NF-kB inhibition — suppresses nuclear translocation of NF-kB, reducing transcription of pro-inflammatory cytokines (TNF-alpha, IL-1beta, IL-6, IL-8)
• IL-10 induction — stimulates production of the anti-inflammatory cytokine IL-10
• Nitric oxide reduction — decreases iNOS expression and nitric oxide production in activated macrophages
• Inflammasome modulation — emerging evidence for NLRP3 inflammasome suppression

Notably, the anti-inflammatory activity of alpha-MSH has been mapped to its C-terminal tripeptide KPV (residues 11-13), which retains NF-kB inhibitory effects without the melanogenic activity of the full-length peptide. This dissociation of anti-inflammatory from pigmentary effects has been central to the development of KPV as a targeted anti-inflammatory research peptide.

Immunomodulation

Beyond acute anti-inflammatory signaling, alpha-MSH modulates adaptive immunity:

• Promotes tolerogenic dendritic cell differentiation
• Suppresses antigen-specific T cell activation
• Modulates Th1/Th2 cytokine balance toward anti-inflammatory profiles
• Contributes to immune privilege in the eye and brain

Research Summary

Applications

Synthetic Melanocortin Analogs

Alpha-MSH's pharmacophore has been the basis for several clinically significant synthetic peptides:

• Melanotan I (Afamelanotide/Scenesse) — a linear alpha-MSH analog approved in the EU for erythropoietic protoporphyria; provides photoprotective tanning without UV exposure
• Melanotan II — a cyclic melanocortin agonist studied for tanning and sexual dysfunction; precursor to bremelanotide
• Bremelanotide (Vyleesi) — a cyclic MC4R agonist FDA-approved for hypoactive sexual desire disorder in premenopausal women
• Setmelanotide (Imcivree) — an MC4R agonist approved for obesity due to POMC, PCSK1, or LEPR deficiency

Research Significance

Alpha-MSH occupies a central position in several active areas of peptide research:

• Obesity pharmacology — MC4R agonism as a therapeutic strategy for genetic and common obesity
• Anti-inflammatory peptide development — particularly the KPV fragment for gut inflammation
• Pigmentation biology — understanding melanocortin signaling in photoprotection and melanoma risk
• Neuroendocrine integration — the POMC neuron as a model for multi-peptide signaling

Clinical Diagnostics

Alpha-MSH levels are measured in the context of:

• POMC deficiency syndromes
• Ectopic ACTH/MSH production in neuroendocrine tumors
• Pigmentation disorders including vitiligo and Addisonian hyperpigmentation

Dosing Protocols

The following dosing information is compiled from published research and community discussion for educational purposes only. No FDA-approved human dosing guidelines exist for most research peptides. Always consult a qualified healthcare professional.

As an endogenous hormone, alpha-MSH is not typically administered exogenously in clinical practice. Its therapeutic potential is realized through synthetic analogs with improved stability and receptor selectivity:

Native alpha-MSH has a plasma half-life of minutes due to rapid enzymatic degradation, making it unsuitable for direct therapeutic use.

Related Compounds

• KPV — the C-terminal tripeptide (residues 11-13) of alpha-MSH with targeted anti-inflammatory activity via NF-kB inhibition
• ACTH — the 39-amino-acid pituitary hormone containing the full alpha-MSH sequence at its N-terminus
• Melanotan II — a cyclic synthetic melanocortin agonist derived from the alpha-MSH pharmacophore
• Bremelanotide (PT-141) — an MC4R-preferring agonist approved for HSDD, structurally derived from Melanotan II
• Setmelanotide — an MC4R agonist for genetic obesity, representing the therapeutic maturation of alpha-MSH pharmacology
• AgRP (Agouti-Related Peptide) — the endogenous MC3R/MC4R inverse agonist that opposes alpha-MSH in energy homeostasis